



AcouSort AB (publ)
Press release 29 September, 2023

AcouSort to present its unique acoustofluidics technology at the international conference μ TAS 2023

AcouSort's technology makes it possible to fractionate the different cell types in a blood sample, isolate extracellular vesicles, or wash cells to remove contaminants, without having any physical contact with the sample. The technology continues to find its way into an increasing number of life science applications. On October 15-19, 2023, AcouSort will attend μ TAS 2023, the 27th International Conference on Miniaturized Systems for Chemistry and Life Sciences, to present the unique features of its technology.

The μ TAS 2023 conference is expected to attract some 1,000 scientists and industry professionals and focuses on microfluidics/lab-on-a-chip systems for life science applications. AcouSort's presence at the conference will be dedicated to displaying its technology for the cell therapy market, an area which is of rapidly increasing interest for the Company. AcouSort's technology will be presented in the exhibition area as well as in two separate poster presentations:

- One poster is presented by Senior Scientist *Mikael Evander* and addresses the use of AcouTrap technology to isolate and wash stem cells before they are used in therapy
- The other poster is presented by AcouSort's NIH customer *Dr Stephen Adler* and addresses the use of the AcouWash technology for centrifuge-free radiolabeling of immune cells in cancer treatment

Both poster presentations are related to the use of AcouSort's technology in different cell therapy applications. In conjunction with the conference, AcouSort will also release a new application note on the new high-throughput acoustic separation solution for automated processing in cell therapy manufacturing.

" μ TAS 2023 is a perfect conference for us to present our unique technology. Over the past year or so, we have made a significant number of inroads into the cell therapy space. Our ambition now is to establish as many research collaborations as possible to pave the way for future OEM partnerships," says Jessica Congiu, Commercial Product Manager at AcouSort.

FOR FURTHER INFORMATION ON ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com

ABOUT ACOUSORT

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Erik Penser Bank.